Droxidopa Shortage: What Providers and Prescribers Need to Know in 2026

Provider Briefing: Droxidopa Access in 2026

If you prescribe Droxidopa (brand name Northera) for neurogenic orthostatic hypotension (nOH), you're likely aware that getting this medication into your patients' hands has never been straightforward. As a specialty drug with limited distribution channels, prior authorization requirements, and a high cash price, Droxidopa presents unique access challenges that directly impact patient adherence and outcomes.

This guide covers the current availability landscape, prescribing considerations, and practical tools to help your patients obtain Droxidopa in 2026.

Current Availability Picture

Droxidopa remains available in the United States, but access is complicated by several factors:

• Specialty pharmacy distribution: Brand-name Northera is primarily distributed through specialty pharmacies, not standard retail chains. This adds processing time and limits patient options.
• Generic availability: Generic Droxidopa capsules (100mg, 200mg, 300mg) are now available from multiple manufacturers. This has improved access somewhat, with generic versions occasionally stocked at retail pharmacies.
• Prior authorization: Most commercial and Medicare plans require prior authorization for Droxidopa. CoverMyMeds can help streamline this process electronically.
• Price disparity: Brand Northera retails around $2,721 for 90 capsules. Generic versions can be obtained for as low as $36.90 with discount coupons, creating a significant cost gap that influences formulary decisions.

Prescribing Implications

When initiating or continuing Droxidopa therapy, consider these practical factors:

Dosing and Titration

The recommended starting dose is 100mg three times daily (morning, midday, and late afternoon — at least 3 hours before bedtime). Titrate in 100mg increments every 24–48 hours up to a maximum of 600mg three times daily. The timing restriction exists because of the boxed warning for supine hypertension.

Monitoring Requirements

The FDA boxed warning for supine hypertension means providers should:

• Monitor supine blood pressure before and during treatment
• Advise patients to elevate the head of the bed
• Reduce or discontinue if supine hypertension persists

Generic vs. Brand Considerations

With generic Droxidopa now available, prescribers can specify generic substitution to improve access and reduce cost barriers. However, some specialty pharmacies may still default to brand Northera, so explicit generic prescribing or "DAW 0" notation can help.

Cost and Access Barriers

Cost remains the primary barrier to Droxidopa adherence. Here's what to know:

• Cash price: $2,721 (brand) vs. $36.90–$72.04 (generic with coupons)
• Insurance: Most plans cover Droxidopa with prior authorization. Step therapy through Midodrine may be required first.
• Medicare Part D: Covered but may require Tier 4/specialty tier copays
• Copay assistance: The Northera Commercial Copay Assistance Program helps eligible commercially insured patients. See northera.com for details.

For a comprehensive guide on cost-reduction strategies, see our provider's guide to Droxidopa savings programs.

Tools and Resources for Providers

Finding Pharmacies With Stock

Medfinder for Providers can help you and your patients locate pharmacies that currently have Droxidopa in stock, reducing the cycle of phone calls and transfer requests that delays treatment initiation.

Prior Authorization Support

CoverMyMeds offers electronic prior authorization for Northera, connecting your office directly with health plans. Lundbeck also provides support through their patient services team.

Patient Education Resources

Direct patients to these resources:

• What Is Droxidopa? — patient-friendly overview
• How to Save Money on Droxidopa — coupons and assistance programs
• Finding Droxidopa in Stock — practical search tips

Alternative Therapies

When Droxidopa is inaccessible or cost-prohibitive, consider:

• Midodrine: Alpha-1 agonist, widely available generic, often first-line for nOH. Requires TID dosing with upright posture monitoring.
• Fludrocortisone: Off-label mineralocorticoid that increases blood volume. Inexpensive but watch for electrolyte imbalances and supine hypertension.
• Pyridostigmine: Cholinesterase inhibitor, off-label for mild nOH. May be better tolerated but less effective for severe cases.

See our full alternatives guide for detailed comparisons.

Looking Ahead

Generic competition is gradually improving Droxidopa access and pricing. However, the niche patient population (primarily Parkinson's disease, MSA, and PAF patients with nOH) means distribution will likely remain concentrated in specialty channels. Providers who proactively manage prior authorizations, direct patients to coupon programs, and use pharmacy-finding tools like Medfinder can significantly improve their patients' experience.

Final Thoughts

Droxidopa fills an important therapeutic niche for patients with neurogenic orthostatic hypotension. While access challenges persist in 2026, the combination of generic availability, copay assistance programs, and digital pharmacy-finding tools makes it more obtainable than in years past. Staying informed about these resources allows you to advocate effectively for your patients' access to this medication.